ArticleFrontiers in pediatrics2025
Case Report: Fiberoptic bronchoscopy and thoracoscopic surgery as a treatment for pulmonary mucormycosis in pediatric acute lymphoblastic leukemia.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mucormycosis, a severe disease caused by fungal infections of the Mucorales order, is a frequent cause of mortality in patients with hematological malignancies. Pulmonary mucormycosis represents a common form of this condition in pediatric patients with hematological malignancies and is associated with a high mortality rate. Liposomal amphotericin B (L-AmB) remains the primary therapeutic agent for pulmonary mucormycosis, however, its efficacy is often limited. We report a case of treating pulmonary mucormycosis in a pediatric patient with acute lymphoblastic leukemia (ALL) using fiberoptic bronchoscopy (FB) combined with thoracoscopic surgery, in conjunction with antifungal therapy including L-AmB. Case report and management: A 3-year-old male patient with a 1-year history of ALL. After the 11th chemotherapy session, the patient developed symptoms including fever, cough, and sputum production. Comprehensive diagnostic evaluations confirmed the presence of pulmonary mucormycosis in the right lung. On the basis of adequate administration of multiple antifungal agents, we conducted two fiberoptic bronchoscopy-guided bronchoalveolar lavage procedures for the child, successfully confining the lesion to the right upper lobe. However, the child continued to experience intermittent hemoptysis. Subsequently, we performed a thoracoscopic right upper lobectomy for the child. The child was discharged smoothly 9 days after the operation, and the postoperative pathology also indicated a fungal infection. One month postoperatively, a follow-up chest CT scan revealed no significant infection in either lung. Chemotherapy for ALL was continued. The child was followed up for three years after completion of treatment and remained in good health with no notable symptoms. Conclusion: The treatment of childhood ALL complicated with pulmonary mucormycosis is particularly challenging and associated with a high mortality rate. For children with severe infections, combining antifungal therapy, such as L-AmB, with bronchoscopy and thoracoscopic surgery has been shown to be both feasible and effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.